AzTrials
AzTrials

Degenerative Lumbar Spinal StenosisNCT02592642

the Evaluation of Four Non-operative Treatments for Degenerative Lumbar Spinal Stenosis

A study testing Self-management Program, Workbook, Video, Pedometer, Instructional Workbook, Video, and Pedometer and Para-spinal TENS in people with Degenerative Lumbar Spinal Stenosis, run by Mount Sinai Hospital, Canada at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Arthritis of the spine causes narrowing of the spinal canals and compression of the spinal nerves traveling into the legs, limiting walking ability. The vast majority of individuals with arthritis of the spine are not suited for surgery and most receive non-surgical treatment. Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Degenerative Lumbar Spinal Stenosis
What is being tested?
Self-management Program, Workbook, Video, Pedometer, Instructional Workbook, Video, and Pedometer and Para-spinal TENS
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
104 participants
Where
1 siteCanada
Study dates
Sep 2014to 1 Mar 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age greater or equal to 50 years
  • Clinical symptoms of back and/or radiating lower limb or buttock pain; fatigue or loss of sensation in the lower limbs aggravated by walking and/or standing and relieved by sitting
  • Intermittent or persistent pain without progressive neurological dysfunction
  • Duration of symptoms and signs for more than 3 months
  • Imaging confirmed spinal canal narrowing using MRI, CT scan, myelography or ultrasound
  • Clinical signs and symptoms corresponding to segmental level of narrowing identified by imaging
Show all 11Show fewer
  • Patients with degenerative spondylolisthesis are included
  • Not considered to be a surgical candidate (in the next 12 months) or patient unwilling to have surgery
  • Able to perform mild-moderate exercise
  • Able to walk without assistive devices for at least 20 metres and less than 30 minutes continuously
  • Able to give written informed consent and complete interviews and questionnaires in English.

Who cannot join

  • Severe degenerative stenosis with intractable pain and progressive neurological dysfunction
  • Lumbar spinal stenosis not caused by degeneration
  • Lumbar herniated disc diagnosed during the last 12 months
  • Previous back surgery for lumbar spinal stenosis or instability
  • Underlying spinal disorder such as ankylosing spondylitis, neoplasm, infection or metabolic disease
  • Intermittent claudication due to vascular disease
Show all 9Show fewer
  • Severe osteoarthrosis or arthritis of lower extremities causing limited walking ability
  • Neurologic disease causing impaired function of the lower limbs, including diabetes
  • Psychiatric disorders and /or cognitively impaired

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Mount Sinai Hospital

    Toronto, Ontario, M5T 3L9

Other trials in Canada

About this study

Official title: Self-Management to Improve Walking Ability in Degenerative Lumbar Spinal Stenosis: the Evaluation of Four Novel Strategies.

Arthritis of the spine causes narrowing of the spinal canals and compression of the spinal nerves traveling into the legs, limiting walking ability. The vast majority of individuals with arthritis of the spine are not suited for surgery and most receive non-surgical treatment. However, we do not know what non-surgical treatments are effective in improving walking in these people. The purpose of our research is to test four new treatments for arthritis of the spine to see if they can improve walking ability. Each treatment approach focuses on the changes that occur in the spine and the whole person as a result of the arthritis that directly or indirectly impacts the ability to walk and perform usual daily activities. Because arthritis of the spine is a chronic condition usually does not go away, it is important that people acquire the knowledge, skills, and tools to manage their condition on their own. The treatments that investigators plan to test as part of this research proposal are aimed at achieving this goal. However, before the investigators can promote the use of these treatments they need to formally test them using strict scientific methods to make sure they do more good than harm. The four treatments include 1) a six week training program referred to as "Boot Camp for Stenosis" which provides one-on-one training on exercise and self-management strategies 2) a patient educational workbook and video on how to self-manage, 3) an electrical device that is placed on the lower back to reduce nerve pain when walking and 4) a spinal stenosis belt that people can wear to reduce pressure on the nerves while walking. The plan is to assess the change in walking distance using the various treatments and assess what impact the treatments have on peoples' overall function and quality of life. Innovative treatment approaches with a long term perspective are urgently needed to deal with the growing number of people with arthritis of the spine who are disabled. It is likely that there is not one solution to this problem - many people will require more than one type of treatment, but an important first step is to determine which treatments are effective, then tailor the treatments to the needs of each person.

Read the detailed description

Degenerative lumbar spinal stenosis (DLSS) or osteoarthritis of the spine is a leading cause of pain, disability, and loss of independence in older adults. It is a chronic disease caused by age related degenerative narrowing (stenosis) of the spinal canal that can lead to compression and ischemia of the spinal nerves (neuro-ischemia). The clinical syndrome of DLSS is known as neurogenic claudication. It is characterized by bilateral or unilateral buttock and/or lower extremity pain, heaviness, numbness, tingling or weakness, precipitated by walking and standing and relieved by sitting and bending forward. Limited walking ability is the dominant functional impairment caused by DLSS. Those afflicted have greater walking limitations than individuals with knee or hip osteoarthritis and greater functional limitations than those with congestive heart failure, chronic obstructive lung disease or systemic lupus erythematosus. Inability to walk among individuals with DLSS leads to a sedentary lifestyle and a progressive decline in health status. The prevalence and economic burden of DLSS is growing exponentially due to the aging population. Although DLSS is the most common reason for spine surgery in individuals over the age of 65, only very few DLSS patients receive surgery. The vast majority of individuals with DLSS receive non-surgical care. However, what constitutes effective non-surgical care is unknown. Self-management strategies may be a practical and effective means to improve walking ability, functional status, and quality of life in this chronic arthritic and often progressive condition. The investigators have conducted two systematic reviews of the literature, one assessing the effectiveness of non-surgical treatments for neurogenic claudication which included randomized controlled trials (RCTs) assessing improvements in pain, disability, quality of life or global improvement; the other evaluated the effectiveness of surgical or non-surgical interventions and included only RCTs that assessed improved walking ability. the investigators learned from these reviews that the evidence for interventions that improve outcomes including walking ability in neurogenic claudication due to DLSS is lacking. The evidence published thus far on this topic has been of low or of very low quality, prohibiting the formulation of evidence-based recommendations for clinical practice. Moreover, the investigators identified no RCTs that examined a self-management approach to the treatment of DLSS.

In addition to the structural arthritic changes causing narrowing of the spinal canal, DLSS has an important dynamic component. The volume of the spinal canal and degree of epidural pressure and ischemia of the spinal nerves can change depending on spinal posture. Both lumbar flexion (stooping forward), and sitting increase the diameter of the canal and reduce spinal nerve ischemia, and correspond with a reduction or elimination of lower extremity symptoms. Conversely, lumbar extension or increasing the lumbar lordosis (which occurs when standing) reduces the diameter of the spinal canal and increases spinal nerve ischemia, and corresponds with increased lower extremity symptoms. The ability to reduce symptoms of DLSS by changing spinal posture/structural alignment and/or increasing blood flow to the spinal nerve provides potential mechanisms for developing interventions to improve symptoms and walking ability.

First, the investigators have designed and implemented a novel six week self-management training program for DLSS over the past 3 years at the Spinal Stenosis Clinic at the Rebecca MacDonald Centre for Arthritis and Auto-immune Diseases at Mount Sinai Hospital (MSH). The goal of the training program is to provide patients with the knowledge, skills, self-confidence, and physical capacity to manage their symptoms and maximize their function. The program is multi-modal, tailored and directed to the structural, functional, physiological and psychosocial consequences of DLSS. Particular emphasis is placed on exercise instruction to build core and lower extremity strength and enable individuals to achieve optimal posture during standing and walking.

There are numerous human studies demonstrating significant reduction in laboratory induced ischemic pain in the lower and upper extremities with paraspinal TENS compared to placebo TENS. Moreover, there is low quality evidence from one case series suggesting that electrical stimulation may be effective for the management of neurogenic claudication. Higher quality studies are needed to assess whether paraspinal TENS applied while walking improves walking ability, as this could be an innovative, convenient, and inexpensive self-management strategy for DLSS patients.

Finally, the investigators have designed a prototype spinal stenosis belt with the Ontario College of Art and Design. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum with the aim to reduce the lumbar lordosis and maximize the spinal canal diameter when walking. The investigators hypothesize the belt will reduce the lumbar lordosis and alleviate epidural pressure and neuro-ischemia while standing and walking. The investigators identified two preliminary studies evaluating back belts, supports or braces for DLSS, none of which were RCTs. These studies found significant improvements in walking distance with the use of a back corset; however both studies had a high risk of bias.

OBJECTIVES AND HYPOTHESES The overall goal of this study is to assess the effectiveness of four self-management strategies in improving walking ability among patients with DLSS. The investigators primary objective is to compare the effectiveness of a comprehensive six week self-management training program that includes a patient instructional workbook, video and pedometer to a patient workbook, video and pedometer alone. The investigators secondary objectives are: 1) to compare the change in walking capacity from baseline when using superficially applied para-spinal TENS versus placebo para-spinal TENS applied during walking and 2) to compare the change in walking capacity from baseline while wearing a novel spinal stenosis belt to the use of a sham spinal stenosis belt while walking. The investigators hypothesize that the self-management training program with workbook, video and pedometer will be more effective in improving walking capacity and functional outcomes than the use of a workbook, video and pedometer alone. Furthermore, the investigators hypothesize that para-spinal TENS or the novel spinal stenosis belt used while walking will be more effective in improving walking capacity than placebo TENS or a sham spinal stenosis belt, respectively.

Being tested
Self-management Program, Workbook, Video, Pedometer, Instructional Workbook, Video, and Pedometer, Para-spinal TENS, Para-spinal Placebo TENS, Prototype Spinal Stenosis Belt
Keywords
lumbar spinal stenosis, neurogenic claudication, non-operative, treatment, outcomes, clinical trial
Medical subject headings
Spinal Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Self-management Program, Workbook, Video, PedometerBehavioural

    Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.

  • Instructional Workbook, Video, and PedometerBehavioural

    Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.

  • Para-spinal TENSDevice

    Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.

  • Para-spinal Placebo TENSDevice

    Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine [NeuroTrac TENS from Verity Medical Ltd (U.K.)] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).

  • Prototype Spinal Stenosis BeltDevice

    Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.

  • Sham Spinal Stenosis BeltDevice

    Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.

Study groups in NCT02592642
Study groupRoleWhat they receive
Group 1ExperimentalSelf-management Program, Workbook, Video, Pedometer
Receives: Behavioral: Self-management Program, Workbook, Video, Pedometer
Group 2Active comparatorInstructional Workbook, Video, and Pedometer
Receives: Behavioral: Instructional Workbook, Video, and Pedometer
Group aExperimentalPara-spinal TENS
Receives: Device: Para-spinal TENS
Group bPlacebo comparatorPara-spinal Placebo TENS
Receives: Device: Para-spinal Placebo TENS
Group cExperimentalPrototype Spinal Stenosis Belt
Receives: Device: Prototype Spinal Stenosis Belt
Group dSham comparatorSham spinal stenosis belt
Receives: Device: Sham Spinal Stenosis Belt

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in The Self-Paced Walk Test

    The Self-Paced Walk Test requires subjects to walk on a level surface without support at their own pace until forced to stop due to symptoms of DLSS or after a time limit of 30 minutes (54). Test termination will be defined as a complete stop of 3 seconds. A blinded assessor will follow one meter behind the subject, without conversing, with a distance instrument (Lufkin Pro-Series Model PSMW38), and stop watch. Distance walked and time to test termination will be recorded.

    Measured: Change from baseline to 6 weeks (immediately post-intervention), 3 months, 6 months, and 12 months post-intervention

Secondary outcomes (5)
  1. Zurich Claudication Questionnaire

    The Zurich Claudication Questionnaire (ZCQ), also known as the Swiss Spinal Stenosis Scale, will be used as a measure of physical function and symptom severity. The questionnaire consists of three scales; a physical performance scale, a symptom severity scale, and a patient satisfaction scale (56, 57). The physical performance scale consists of five questions related to walking ability. The mean un-weighted score will be calculated. The symptom scale consists of seven questions pertaining to overall severity of pain, pain frequency, back pain and, pain in the leg, numbness, weakness, and balance disturbance.

    Measured: change from baseline to 6 weeks (immediately post-intervention), 3 months, 6 months, and 12 months post-intervention

  2. Oswestry Disability Index

    The Oswestry Disability Index will be used to assess back related disability. The total score will be calculated where 0 represents no disability and 100 represent the worse possible disability. We will also record separately the score of the walking section (ODI walk) of the ODI.

    Measured: change from baseline to 6 weeks (immediately post-intervention), 3 months, 6 months, and 12 months post-intervention

  3. Numeric Rating Scale

    The Numeric Rating Scale will be used to assess leg and back pain intensity while walking. It is an 11-point scale anchored by two extremes of pain intensity ranging from 0 (referring to "No pain") to 10 (referring to "Pain as bad as it could be").

    Measured: change from baseline to 6 weeks (immediately post-intervention), 3 months, 6 months, and 12 months post-intervention

  4. Medical Outcomes Study Short-Form Health Survey version two (SF-36)

    We will use the Medical Outcomes Study Short-Form Health Survey version two (SF-36) to measure health-related quality of life (H-RQoL). The SF-36 has 36 items which measure the H-RQoL of a subject. Two summary scores can be computed: the physical component score and the mental component score.

    Measured: change form baseline to 6 weeks (immediately post-intervention), 3 months, 6 months, and 12 months post-intervention

  5. Centre for Epidemiological Studies Depression Scale

    The Center for Epidemiological Studies-Depression Scale (CES-D) will be used to measure depressive symptomatology in the previous week. The CES-D is a widely used 20-item self-report scale designed to measure current level of depressive symptomatology in population-based epidemiologic research (65).

    Measured: Change from baseline to 6 weeks (immediately post-intervention), 3 months, 6 months, and 12 months post-intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2015 (estimated)
  2. Study startSep 2014
  3. Primary completion15 Feb 2017
  4. Study completion1 Mar 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
104 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02592642
Sponsor's protocol ID
SOG-13-003
Status last verified
Aug 2017
First submitted
27 Oct 2015
Last updated
30 Aug 2017
Results posted
No
Data monitoring committee
No

Publications

  • Fanuele JC, Birkmeyer NJ, Abdu WA, Tosteson TD, Weinstein JN. The impact of spinal problems on the health status of patients: have we underestimated the effect? Spine (Phila Pa 1976). 2000 Jun 15;25(12):1509-14. doi: 10.1097/00007632-200006150-00009.

    PubMed 10851099
  • Takahashi K, Kagechika K, Takino T, Matsui T, Miyazaki T, Shima I. Changes in epidural pressure during walking in patients with lumbar spinal stenosis. Spine (Phila Pa 1976). 1995 Dec 15;20(24):2746-9. doi: 10.1097/00007632-199512150-00017.

    PubMed 8747254
  • Diggle P. Analysis of longitudinal data. Press OU, editor. New York2009.

  • Katz JN, Dalgas M, Stucki G, Katz NP, Bayley J, Fossel AH, Chang LC, Lipson SJ. Degenerative lumbar spinal stenosis. Diagnostic value of the history and physical examination. Arthritis Rheum. 1995 Sep;38(9):1236-41. doi: 10.1002/art.1780380910.

    PubMed 7575718
  • Suri P, Rainville J, Kalichman L, Katz JN. Does this older adult with lower extremity pain have the clinical syndrome of lumbar spinal stenosis? JAMA. 2010 Dec 15;304(23):2628-36. doi: 10.1001/jama.2010.1833.

    PubMed 21156951
  • Winter CC, Brandes M, Muller C, Schubert T, Ringling M, Hillmann A, Rosenbaum D, Schulte TL. Walking ability during daily life in patients with osteoarthritis of the knee or the hip and lumbar spinal stenosis: a cross sectional study. BMC Musculoskelet Disord. 2010 Oct 12;11:233. doi: 10.1186/1471-2474-11-233.

    PubMed 20939866
  • Iversen MD, Katz JN. Examination findings and self-reported walking capacity in patients with lumbar spinal stenosis. Phys Ther. 2001 Jul;81(7):1296-306.

    PubMed 11444993
  • Jonsson B, Annertz M, Sjoberg C, Stromqvist B. A prospective and consecutive study of surgically treated lumbar spinal stenosis. Part I: Clinical features related to radiographic findings. Spine (Phila Pa 1976). 1997 Dec 15;22(24):2932-7. doi: 10.1097/00007632-199712150-00016.

    PubMed 9431629
  • Jansson KA, Nemeth G, Granath F, Jonsson B, Blomqvist P. Health-related quality of life (EQ-5D) before and one year after surgery for lumbar spinal stenosis. J Bone Joint Surg Br. 2009 Feb;91(2):210-6. doi: 10.1302/0301-620X.91B2.21119.

    PubMed 19190056
  • Deyo RA, Mirza SK, Martin BI, Kreuter W, Goodman DC, Jarvik JG. Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. JAMA. 2010 Apr 7;303(13):1259-65. doi: 10.1001/jama.2010.338.

    PubMed 20371784
  • Chen E, Tong KB, Laouri M. Surgical treatment patterns among Medicare beneficiaries newly diagnosed with lumbar spinal stenosis. Spine J. 2010 Jul;10(7):588-94. doi: 10.1016/j.spinee.2010.02.026. Epub 2010 Apr 8.

    PubMed 20381431
  • Ammendolia C, Stuber K, de Bruin LK, Furlan AD, Kennedy CA, Rampersaud YR, Steenstra IA, Pennick V. Nonoperative treatment of lumbar spinal stenosis with neurogenic claudication: a systematic review. Spine (Phila Pa 1976). 2012 May 1;37(10):E609-16. doi: 10.1097/BRS.0b013e318240d57d.

    PubMed 22158059
  • Tran DQ, Duong S, Finlayson RJ. Lumbar spinal stenosis: a brief review of the nonsurgical management. Can J Anaesth. 2010 Jul;57(7):694-703. doi: 10.1007/s12630-010-9315-3. Epub 2010 Apr 29.

    PubMed 20428988
  • May S, Comer C. Is surgery more effective than non-surgical treatment for spinal stenosis, and which non-surgical treatment is more effective? A systematic review. Physiotherapy. 2013 Mar;99(1):12-20. doi: 10.1016/j.physio.2011.12.004. Epub 2012 Apr 16.

    PubMed 23219644
  • Atlas SJ, Keller RB, Wu YA, Deyo RA, Singer DE. Long-term outcomes of surgical and nonsurgical management of lumbar spinal stenosis: 8 to 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976). 2005 Apr 15;30(8):936-43. doi: 10.1097/01.brs.0000158953.57966.c0.

    PubMed 15834339

Questions about this trial

What is this clinical trial studying?

A study testing Self-management Program, Workbook, Video, Pedometer, Instructional Workbook, Video, and Pedometer and Para-spinal TENS in people with Degenerative Lumbar Spinal Stenosis, run by Mount Sinai Hospital, Canada at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in The Self-Paced Walk Test (time frame: Change from baseline to 6 weeks (immediately post-intervention), 3 months, 6 months, and 12 months post-intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02592642, which also lists 76 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in